FDA OKs 'Game-Changer' Oral GLP-1 Agonist for Type 2 Diabetes

medscape.com - The US Food and Drug Administration has approved oral semaglutide (Rybelsus, Novo Nordisk), 7 mg and 14 mg, for the treatment of type 2 diabetes in adults to improve glycemic control along with diet …